{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:54:03Z","timestamp":1774583643497,"version":"3.50.1"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Key R&D Program of China","award":["2017YFC0909301"],"award-info":[{"award-number":["2017YFC0909301"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81603275"],"award-info":[{"award-number":["81603275"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81602627"],"award-info":[{"award-number":["81602627"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Project of Innovation Team","award":["LT2015027"],"award-info":[{"award-number":["LT2015027"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ejmech.2018.02.001","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T02:33:33Z","timestamp":1517798013000},"page":"205-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives"],"prefix":"10.1016","volume":"147","author":[{"given":"Dejuan","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingjuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dahong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leilei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.02.001_bib1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1126\/science.6264599","article-title":"Biology of hepatitis B virus","volume":"213","author":"Tiollais","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.02.001_bib2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/fcp.12053","article-title":"Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors","volume":"28","author":"Qiu","year":"2014","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.med.45.1.297","article-title":"Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma","volume":"45","author":"Robinson","year":"1994","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2018.02.001_bib4","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1086\/656624","article-title":"Review of hepatitis B therapeutics","volume":"51","author":"Bhattacharya","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2018.02.001_bib5","first-page":"117","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"38","author":"Naghavi","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2018.02.001_bib6","series-title":"Hepatitis B: World Health Organization Fact Sheet 204","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.ejmech.2018.02.001_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association for the Study of the Liver","year":"2012","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib8","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3169","article-title":"Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicenter trial","author":"Lee","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2018.02.001_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7075935","article-title":"Efficacy of nucleot(s)ide analogs therapy in patients with unresectable HBV-related hepatocellular carcinoma: a systematic review and meta-analysis","author":"He","year":"2017","journal-title":"Dis. Markers"},{"key":"10.1016\/j.ejmech.2018.02.001_bib10","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1002\/jmv.20608","article-title":"Hepatitis B virus mutations associated with antiviral therapy","volume":"78","author":"Bartholomeusz","year":"2006","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172101","article-title":"Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population","author":"Gencay","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.02.001_bib12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1053\/j.gastro.2003.06.005","article-title":"Enterohepatic bile salt transporters in normal physiology and liver disease","volume":"126","author":"Kullak-Ublick","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2018.02.001_bib13","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2018.02.001_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-6700-1_1","article-title":"NTCP-reconstituted in\u00a0vitro HBV infection system","volume":"1540","author":"Sun","year":"2017","journal-title":"Meth. Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib15","doi-asserted-by":"crossref","first-page":"9849","DOI":"10.1073\/pnas.1730940100","article-title":"Nuclear import of hepatitis B virus capsids and release of the viral genome","volume":"100","author":"Rabe","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2018.02.001_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-4939-6700-1_4","article-title":"Intracytoplasmic transport of hepatitis B virus capsids","volume":"1540","author":"Osseman","year":"2017","journal-title":"Meth. Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib17","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1126\/science.1142204","article-title":"Crossing the nuclear envelope: hierarchical regulation of nucleocytoplasmic transport","volume":"318","author":"Terry","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.02.001_bib18","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1172\/JCI86650","article-title":"New perspectives on the hepatitis B virus life cycle in the human liver","volume":"126","author":"Revill","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2018.02.001_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3748\/wjg.v13.i1.39","article-title":"Intracellular transport of hepatitis B virus","volume":"13","author":"Kann","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1128\/JVI.75.2.961-970.2001","article-title":"Baculovirus infection of nondividing mammalian cells: mechanisms of entry and nuclear transport of capsids","volume":"75","author":"van Loo","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020163","article-title":"Host heterogeneousribonucleoprotein K (hnRNPK) as a potential target to suppress hepatitis B virusreplication","volume":"2","author":"Ng","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejmech.2018.02.001_bib22","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2018.02.001_bib23","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.02.001_bib24","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.1128\/JVI.01123-07","article-title":"Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation","volume":"81","author":"Guo","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.69.6.3350-3357.1995","article-title":"The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes","volume":"69","author":"Newbold","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib26","first-page":"309","article-title":"Hepatitis B: the virus and disease","volume":"7","author":"Liang","year":"2009","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.ejmech.2018.02.001_bib27","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/JVI.64.11.5324-5332.1990","article-title":"The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation","volume":"64","author":"Bartenschlager","year":"1990","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib28","doi-asserted-by":"crossref","first-page":"10046","DOI":"10.1073\/pnas.89.21.10046","article-title":"Hepatitis B virus capsid particles are assembled from core-protein dimer precursors","volume":"89","author":"Zhou","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2018.02.001_bib29","doi-asserted-by":"crossref","first-page":"8124","DOI":"10.1128\/JVI.76.16.8124-8137.2002","article-title":"Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein","volume":"76","author":"Daub","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib30","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1002\/j.1460-2075.1991.tb04917.x","article-title":"Sequence-independent RNA cleavages generate the primers for plus strand DNA synthesis in hepatitis B viruses: implications for other reverse transcribing elements","volume":"10","author":"Loeb","year":"1991","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2018.02.001_bib31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jviromet.2013.01.012","article-title":"Optimization of in\u00a0vitro HBV replication and HBsAg production in HuH7 cell line","volume":"189","author":"Cavallone1","year":"2013","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.ejmech.2018.02.001_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/MMBR.64.1.51-68.2000","article-title":"Hepatitis B virus biology","volume":"64","author":"Seeger","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.ejmech.2018.02.001_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hep.26181","article-title":"Myristoylated preS1-domain of the hepatitis B virus L -protein mediates specific binding to differentiated hepatocytes","volume":"58","author":"Meier","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2018.02.001_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3748\/wjg.v13.i1.22","article-title":"Viral and cellular determinants involved in hepadnaviral entry","volume":"13","author":"Glebe","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","article-title":"Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor","volume":"60","author":"Nkongolo","year":"2014","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib36","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/JVI.79.3.1613-1622.2005","article-title":"Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein","volume":"79","author":"Gripon","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib37","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.24758","article-title":"Humanized chimeric uPA mouse model for the study of hepatitis B and D Virus interactions and preclinical drug evaluation","volume":"55","author":"Lutgehetmann","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2018.02.001_bib38","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2013","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","article-title":"Prevention of hepatitis B virus infection in\u00a0vivo by entry inhibitors derived from the large envelope protein","volume":"26","author":"Petersen","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2018.02.001_bib41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/157016111793744760","article-title":"Ezetimibe: more than a low density lipoprotein cholesterol lowering drug? An update after 4 years","volume":"9","author":"Lioudaki","year":"2011","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nm.2581","article-title":"Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor","volume":"18","author":"Sainz","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2018.02.001_bib43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.antiviral.2014.03.017","article-title":"Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle","volume":"106","author":"Blanchet","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2018.02.001_bib44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2012.12.008","article-title":"Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes","volume":"97","author":"Lucifora","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2018.02.001_bib45","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00277-017-2918-9","article-title":"Outcome of anti-thymocyte immunoglobulin plus cyclosporine A for severe aplastic anaemia with chronic hepatitis B virus infection","volume":"96","author":"Chen","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib46","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0006-2952(93)90489-J","article-title":"Differential effects of cyclosporin A on the transport of bile acids by human hepatocytes","volume":"46","author":"Azer","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib47","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1745-7254.2007.00590.x","article-title":"Evaluation of hepatitis B virus replication and proteomic analysis of HepG2.2.15 cell line after cyclosporine A treatment","volume":"28","author":"Xie","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2018.02.001_bib48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jhep.2016.11.009","article-title":"Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity","volume":"66","author":"Shimura","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000360948","article-title":"Inhibitors of hepatitis B virus attachment and entry","volume":"57","author":"Lempp","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.ejmech.2018.02.001_bib50","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbrc.2013.12.052","article-title":"Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP","volume":"443","author":"Iwamoto","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2018.02.001_bib51","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.26982","article-title":"Cyclosporin a and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)","volume":"59","author":"Watashi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2018.02.001_bib52","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.bmc.2015.01.020","article-title":"Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]\u2013APOA1\u2013HBx\u2013Beclin1-mediated autophagic pathway in HBV therapy","volume":"23","author":"Zhang","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.02.001_bib53","doi-asserted-by":"crossref","first-page":"11945","DOI":"10.1128\/JVI.01855-15","article-title":"A\u00a0novel tricyclic polyketide, vanitaracin a, specifically inhibits the entry of hepatitis B and D Viruses by targeting sodium taurocholate cotransporting polypeptide","volume":"89","author":"Kaneko","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib54","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/cpr.12117","article-title":"In silico, analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy","volume":"47","author":"Fu","year":"2014","journal-title":"Cell Prolif"},{"key":"10.1016\/j.ejmech.2018.02.001_bib55","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.antiviral.2015.06.007","article-title":"Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na\u00a0+ -dependent taurocholate cotransporting polypeptide activity","volume":"120","author":"Wang","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2018.02.001_bib56","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.antiviral.2014.09.009","article-title":"(+)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes","volume":"111","author":"Huang","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2018.02.001_bib57","first-page":"549","article-title":"Screening and verifying potential NTCP inhibitors from herbal medicinal ingredients using the LLC-PK1 cell model stably expressing human NTCP","volume":"14","author":"Shen","year":"2016","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.ejmech.2018.02.001_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1742-6405-11-35","article-title":"A\u00a0consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV\/HBV infection","volume":"11","author":"Holt","year":"2014","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.ejmech.2018.02.001_bib59","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0166-3542(01)00216-9","article-title":"Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model","volume":"54","author":"Weber","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2018.02.001_bib60","first-page":"271","volume":"vol. 92","author":"Billiouda","year":"2011"},{"key":"10.1016\/j.ejmech.2018.02.001_bib61","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.02.001_bib62","first-page":"2273","volume":"vol. 66","author":"Hackera","year":"2003"},{"key":"10.1016\/j.ejmech.2018.02.001_bib63","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.antiviral.2016.11.026","article-title":"Exploring the binding mechanism of Heteroaryldihydropyrimidines and Hepatitis B Virus capsid combined 3D-QSAR and molecular dynamics","volume":"137","author":"Tu","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2018.02.001_bib64","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1128\/AAC.46.9.3057-3060.2002","article-title":"Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in\u00a0vitro","volume":"46","author":"Delaney","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.02.001_bib65","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1021\/cb100275b","article-title":"Trapping of Hepatitis B Virus capsid assembly intermediates by phenylpropenamide assembly accelerators","volume":"5","author":"Katen","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib66","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2007.06.014","article-title":"The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging","volume":"76","author":"Felda","year":"2007","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2018.02.001_bib67","doi-asserted-by":"crossref","first-page":"42374","DOI":"10.1038\/srep42374","article-title":"Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2018.02.001_bib68","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00519-17","article-title":"Discovery and mechanistic study of benzamide derivatives that modulate hepatitis B virus capsid assembly","author":"Wu","year":"2017","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib69","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00560-17","article-title":"Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus","author":"Berke","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.02.001_bib70","first-page":"135","article-title":"Hepatitis B virus capsids have diverse structural responses to small molecule ligands bound to the HAP pocket","volume":"12","author":"Venkatakrishnan","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2018.02.001_bib71","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.bmc.2016.12.017","article-title":"Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4)","volume":"25","author":"Ren","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.02.001_bib72","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1128\/AAC.01091-13","article-title":"Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly","volume":"57","author":"Wu","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.02.001_bib73","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3851\/IMP2152","article-title":"In\u00a0vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations","volume":"17","author":"Wang","year":"2012","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2018.02.001_bib74","first-page":"1","article-title":"Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109\/V124 mutations in hepatitis B virus core protein","volume":"9999","author":"Wang","year":"2017","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib75","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1021\/acs.jmedchem.6b00879","article-title":"Design and synthesis of orally bioavailable 4-methyl heteroaryldihydropyrimidine based hepatitis B virus (HBV) capsid inhibitors","volume":"59","author":"Qiu","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.02.001_bib76","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1128\/AAC.01558-15","article-title":"A\u00a0novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation","volume":"59","author":"Wang","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.02.001_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2014.04.005","article-title":"Nucleoside\/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance","volume":"8","author":"Menendez-Arias","year":"2014","journal-title":"Curr. Opin. Virol"},{"key":"10.1016\/j.ejmech.2018.02.001_bib78","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2014","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib79","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. Tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"Sax","year":"2014","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ejmech.2018.02.001_bib80","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3851\/IMP2770","article-title":"Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity","volume":"19","author":"Bam","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2018.02.001_bib81","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/jmv.23982","article-title":"Evaluation of HBV DNA decay kinetics in patients containing both rtM204V\/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)\/TDF","volume":"86","author":"Liu","year":"2014","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib82","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1128\/AAC.01151-15","article-title":"Characterization of HIV-1 resistance to tenofovir alafenamide in\u00a0vitro","volume":"59","author":"Margot","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.02.001_bib83","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/QAI.0000000000001069","article-title":"Brief report: efficacy and safety of switching to a single-tablet regimen of elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide in HIV-1\/hepatitis B-Coinfected adults","volume":"73","author":"Gallant","year":"2016","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ejmech.2018.02.001_bib84","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1128\/AAC.01290-08","article-title":"Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice","volume":"53","author":"Yuen","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.02.001_bib85","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1177\/135965350601100806","article-title":"Dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B","volume":"11","author":"Yuen","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2018.02.001_bib86","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1128\/AAC.00599-13","article-title":"Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine","volume":"57","author":"Jones","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.02.001_bib87","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1128\/AAC.00001-07","article-title":"Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues","volume":"51","author":"Matthes","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.02.001_bib88","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(86)90602-1","article-title":"Formation of the pool of covalently closed circular viral DNA in hepadnavirus infected cells","volume":"47","author":"Tuttleman","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2018.02.001_bib89","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1128\/JVI.69.6.3350-3357.1995","article-title":"The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes","volume":"69","author":"Newbold","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib90","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2018.02.001_bib91","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.00473-12","article-title":"Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation expression of HBV genes","volume":"56","author":"Cai","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.02.001_bib92","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.antiviral.2016.08.008","article-title":"Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation","volume":"133","author":"Tanaka","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2018.02.001_bib93","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2016.08.026","article-title":"Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA","volume":"134","author":"Liu","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2018.02.001_bib94","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.antiviral.2013.06.007","article-title":"\u03b2-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity","volume":"99","author":"Hu","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2018.02.001_bib95","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.antiviral.2013.09.007","article-title":"Antiviral activity of methyl helicterate isolated from Helicteres angustifolia (Sterculiaceae) against hepatitis B virus","volume":"100","author":"Huang","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2018.02.001_bib96","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.bmc.2012.11.037","article-title":"Synthesis and biological evaluation of helioxanthin analogues","volume":"21","author":"Janmanchi","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.02.001_bib97","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/095632020501600305","article-title":"Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative","volume":"16","author":"Li","year":"2005","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ejmech.2018.02.001_bib98","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.drudis.2015.01.008","article-title":"Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA","volume":"20","author":"Ahmed","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2018.02.001_bib99","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/mt.2013.31","article-title":"Hepatocyte targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection","volume":"21","author":"Wooddell","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2018.02.001_bib100","first-page":"1305","article-title":"ARC-520 RNAi therapeutic reduces hepatitis B virus DNA, S antigen and e antigen in a chimpanzee with a very high viral titer","volume":"58","author":"Lanford","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2018.02.001_bib101","first-page":"1","article-title":"Safety, tolerability, and pharmacokinetics of ARC-520 injection, an RNA interference-based therapeutic for the treatment of chronic hepatitis B virus infection, in healthy volunteers","volume":"00","author":"Schluep","year":"2016","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejmech.2018.02.001_bib102","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2015.06.019","article-title":"Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent","volume":"121","author":"Gish","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2018.02.001_bib103","doi-asserted-by":"crossref","first-page":"7707","DOI":"10.3748\/wjg.v20.i24.7707","article-title":"Emerging antivirals for the treatment of hepatitis B","volume":"20","author":"Wang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140909","article-title":"Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection","volume":"10","author":"Noordeen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.02.001_bib105","article-title":"REP 9 AC: a potent HBsAg release inhibitor that elicits durable immunological control of chronic HBV infection","volume":"54","author":"Mahtab","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2018.02.001_bib106","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/AAC.00541-07","article-title":"A\u00a0substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion","volume":"51","author":"Dougherty","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.02.001_bib107","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1021\/jm200696v","article-title":"Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion","volume":"54","author":"Yu","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.02.001_bib108","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.antiviral.2014.04.002","article-title":"Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion","volume":"107","author":"Xu","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2018.02.001_bib109","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2013.11.007","article-title":"Antiviral activity of chemical compound isolated from Artemisia morrisonensis against hepatitis B virus in\u00a0vitro","volume":"101","author":"Huang","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2018.02.001_bib110","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib111","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.bmc.2005.11.008","article-title":"Phosphoramidate and phosphate prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine: synthesis, anti-HIV activity and stability studies","volume":"14","author":"Liang","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.02.001_bib112","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3851\/IMP2580","article-title":"Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-alpha2a and adefovir","volume":"18","author":"Takkenberg","year":"2013","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.ejmech.2018.02.001_bib113","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon alfa-2a increases loss of hepatitis b surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2018.02.001_bib114","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1021\/jo500382v","article-title":"Stereoselective synthesis of 2' - fluoro - 6' - methylene carbocyclic adenosine via Vince lactam","volume":"79","author":"Singh","year":"2014","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2018.02.001_bib115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A\u00a0one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group","volume":"339","author":"Lai","year":"1998","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.02.001_bib116","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jcv.2014.06.005","article-title":"Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus","volume":"61","author":"Yu","year":"2014","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.ejmech.2018.02.001_bib117","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","article-title":"A\u00a01-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"129","author":"Lai","year":"2005","journal-title":"Gastroenterology"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418301235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418301235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T18:24:55Z","timestamp":1660415095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418301235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":117,"alternative-id":["S0223523418301235"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.02.001","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}